About
Embolization Microspheres for Imaging
Areas of Focus
Categories
Diagnostics
Team (14)
Aaron Berez
Board Chairman
ABK Biomedical
board_chair
Anthony Headley
Sr. VP, Manufacturing, R&D and Engineering
ABK Biomedical
executive
Aravind Arepally
Chief Medical Officer
ABK Biomedical
executive
Carissa Bellardine Black
Director
ABK Biomedical
team_member
David Dobrowski
Sr. VP of Clinical Development and Regulatory Affairs
ABK Biomedical
executive
Gary Donofrio
Chief Business Officer
ABK Biomedical
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
228
By Phase
NA: 2PHASE2: 1
By Status
RECRUITING: 1COMPLETED: 1UNKNOWN: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05953337Lead Sponsor
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
NARecruiting
120 participants
Started: Sep 21, 2023 · Completed: Oct 31, 2025
NCT04926376Lead Sponsor
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)
NACompleted
8 participants
Started: Nov 2, 2021 · Completed: Nov 13, 2023
NCT03883802Collaborator
Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer
PHASE2Unknown
100 participants
Started: Apr 12, 2019 · Completed: Dec 14, 2024
Locations (1)
Headquarters
Halifax, NS, Canada
Map
Loading map...